<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1009">
  <stage>Registered</stage>
  <submitdate>19/01/2006</submitdate>
  <approvaldate>9/02/2006</approvaldate>
  <actrnumber>ACTRN12606000058572</actrnumber>
  <trial_identification>
    <studytitle>Early Intervention in Acute Renal Failure</studytitle>
    <scientifictitle>A multi-site randomised phase IV study to evaluate the effectiveness of intravenous erythropoietin in preventing intensive care unit patients with acute kidney injury from developing acute renal failure.</scientifictitle>
    <utrn />
    <trialacronym>EARLY ARF 2</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Renal Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous Erythropoietin  in 2 doses at 0 and 24 hours after the detection of a raised urinary acute kidney injury index</interventions>
    <comparator>placebo in 2 doses at 0 and 24 hours after the detection of a raised urinary acute kidney injury index</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The achieved plasma creatinine levels</outcome>
      <timepoint>7 days after randomisation. Plasma creatinine will be monitored for up to 12 months after the intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dialysis free survival</outcome>
      <timepoint>Patients will be followed up for 12 months after enrollment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dialysis free interval</outcome>
      <timepoint>Patients will be followed up for 12 months after enrollment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of ICU stay</outcome>
      <timepoint>Patients will be followed up for 12 months after enrollment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality rate</outcome>
      <timepoint>Patients will be followed up for 12 months after enrollment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>eGFR (estimated Glomerular Filtration Rate)</outcome>
      <timepoint>Patients will be followed up for 12 months after enrollment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Creatinine at 30 days.</outcome>
      <timepoint>Patients will be followed up for 12 months after enrollment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Gamma Glutamyl Transpeptidase X Alkaline Phosphatase index of &gt;46.3 u/mmol. 2. Likely survival &gt;72 hours. 3. Consent obtained.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Active cytotoxic chemotherapy in progress2. Pre existing renal disease (serum creatinine &gt;0.345 mmol/L)3. presence of rhabdomyolysis and/or myoglobinuria4. Already enrolled in another interventional study or previously enrolled in this study5. Increase of plasma creatinine of &gt; 43 Âµmol/L over the previous 24 hours.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The pharmacy department will allocate blinded drug/placebo containing syringes according to a stratified randomisation process.</concealment>
    <sequence>A random number generator has been used and stratified for location. The generator of random number is in-house software developed specifically for randomisation in clinical trials wriiten in visual basic.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>23/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>130</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>The Health Research Council of New Zealand</primarysponsorname>
    <primarysponsoraddress>PO Box 5541, Wellesley Street, Auckland, New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>The Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients admitted to a general intensive care unit and high risk post cardiothoracic surgery patients will be screened for renal injury using urinary biomarkers and randomised within 6 hours of admission to two doses of placebo or erythropoietin at 24 hour intervals. Subjects, investigators and treating clinicians will be blinded to  
treatment throughout the study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi-regional ethics-the Intensive Care Units in Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional ethics-the Intensive Care Units in Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Zoltan Endre</name>
      <address>Head of Department
Department of Medicine
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch</address>
      <phone>+64 0 33641847</phone>
      <fax>+64 0 33640935</fax>
      <email>zoltan.endre@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr John Pickering</name>
      <address>Research Manager/Research Fellow
 Christchurch Kidney Research Group Department of Medicine Christchurch School of Medicine and Health Sciences PO Box 4345 Christchurch</address>
      <phone>+64 0 33641112</phone>
      <fax>+64 0 33640935</fax>
      <email>john.pickering@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr John Pickering</name>
      <address />
      <phone />
      <fax />
      <email>john.pickering@otago.ac.nz</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>